Who is sponsoring NCT05811546?

NCT05811546 is sponsored by Assiut University.

What drugs are being tested in NCT05811546?

Interventions in NCT05811546: Immunohistochemical staining for DNMT1 and EZH2.

What condition does NCT05811546 study?

NCT05811546 studies Gastric Carcinoma.

Is NCT05811546 still recruiting?

NCT05811546 is currently status unknown. Last updated 13 April 2023.

Last reviewed 2023-04-13 · How we verify

NCT05811546

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma

Status unknown Last updated 13 April 2023

What this trial tests

trial testing Immunohistochemical staining for DNMT1 and EZH2 in Gastric Carcinoma in 68 participants. Status unknown.

Timeline

1 May 2022

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	68
Start date	1 May 2022
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across Egypt

Drugs / interventions tested

Immunohistochemical staining for DNMT1 and EZH2

Conditions studied

Gastric Carcinoma — all drugs for Gastric Carcinoma →

Sponsor

Assiut University

Who can join

Adults 30 to 100, any sex, with Gastric Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this cross-sectional study is to evaluate epigenetic modifications in gastric carcinogenesis, mainly in H. pylori gastritis vs gastric carcinoma. The main question\[s\] it aims to answer are: * How does H. pylori infection cause gastric cancer? * Can DNA methylation and other epigenetic changes predict and affect the development of gastric cancer? Formalin-fixed-paraffin-embedded tissue specimens will be obtained and reviewed for comparison between epigenetic changes in H. pylori gastritis and gastric adenocarcinoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications.
Akter S, Madhuvilakku R, Kar AK, Nila IS, et al · · 2026 · PMID 41881983 · DOI 10.1038/s41392-026-02583-x

Verify or expand the search:

Other recruiting trials for Gastric Carcinoma

Currently open trials in the same condition.

NCT07283939 — Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays · NA · recruiting
NCT07315750 — A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab Wi · Phase 3 · recruiting
NCT07139418 — The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gas · recruiting
NCT07108855 — Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green Duri · Phase 1, PHASE2 · recruiting
NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05811546 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 13 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05811546.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing